New therapeutic strategies for the treatment of Parkinson's disease

© 2012 EPFL

Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson’s Disease.

Several lines of evidence suggest that phosphorylation of α-synuclein (α-syn) at S87 or S129 may play an important role in regulating its aggregation, fibrillogenesis, Lewy body formation, and neurotoxicity in vivo. However, whether phosphorylation at these residues enhances or protects against α-syn toxicity in vivo remains unknown. In this study, The groups of Hilal Lashuel (LMNN - Laboratory of Molecular Neurobiology and Neuroproteomics ) and Patrick Aebischer (LEN - Neurodegenerative Studies Laboratory ) investigated the cellular and behavioral effect of overexpression of wild-type (WT), S87A, and S87E α-syn to block or to mimic S87 phosphorylation, respectively, in the substantia nigra of Wistar rats using recombinant adeno-associated vectors. They demonstrate, for the first time, that mimicking phosphorylation at S87 inhibits α-syn aggregation and protects against α-syn-induced toxicity in vivo, suggesting that phosphorylation at this residue would play an important role in controlling α-syn neuropathology. In addition, their results provide strong evidence for a direct correlation between α-syn-induced neurotoxicity, fiber pathology, and motor impairment and the extent of α-syn aggregation in vivo, suggesting that lowering α-syn levels and/or blocking its aggregation are viable therapeutic strategies for the treatment of Parkinson’s disease and related synucleinopathies.

Abid Oueslati et al., The Journal of Neuroscience, 32(5): 1536-1544; doi: 10.1523/JNEUROSCI.3784-11.2012 (2012)

Fauvet B, et al., J Biol Chem. 2012 Feb 7. [Epub ahead of print]